Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 2/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148607 | 0.84 | RECQL (0.44) | RECQLCNR1TSHRCCR2CHRNB2 | |
| SCHEMBL20148605 | 0.83 | RECQL (0.47) | RECQLCNR1TSHRCCR2CHRNB2 | |
| SCHEMBL20071310 | 0.81 | RECQL (0.44) | RECQLCNR1TSHRCCR2CHRNB2 | |
| SCHEMBL20071302 | 0.78 | HRH3 (0.40) | RECQLCNR1TSHRCCR2CHRNB2 | |
| SCHEMBL22030752 | 0.76 | RECQL (0.44) | RECQLCNR1TSHRCCR2CHRNB2 | |
| SCHEMBL20071315 | 0.74 | PIK3CD (0.40) | RECQLCNR1CCR2CHRNB2CHRNA3 | |
| SCHEMBL26203668 | 0.74 | RECQL (0.46) | RECQLCNR1TSHRCHRNB2CHRNA3 | |
| SCHEMBL20070420 | 0.73 | PIK3CD (0.49) | TSHRCCR2 | |
| SCHEMBL20148606 | 0.73 | MAPT (0.38) | RECQLCNR1TSHRCCR2CHRNB2 | |
| SCHEMBL21738123 | 0.72 | HRH3 (0.41) | RECQLCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RECQL 835/4885CNR1 3884/4885TSHR 1461/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RECQL 835/4885CNR1 3884/4885TSHR 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.